MedTrace Logo

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01336205 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 844

Last updated 2014-10-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.

Conditions

  • Opioid-Induced Constipation (OIC)

Interventions

DRUG

NKTR-118

25 mg oral tablet once daily

DRUG

Usual care

As prescribed by the investigator

Sponsors & Collaborators

Principal Investigators

  • Mark Sostek · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01336205 on ClinicalTrials.gov